Although all of the HER2 alterations were demonstrated to be a potential negative prognostic factor in patients with NSCLC for survival both in early and advanced diseases, aiming to target these alterations in NSCLC had disappointing outcomes for decades [18,21,22]. Here, ERBB2 is linked to non-small cell lung carcinoma.